


**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



EP 00 / 5261 **Bescheinigung**

4

Die BASF Aktiengesellschaft in Ludwigshafen/Deutschland hat eine Patent-
anmeldung unter der Bezeichnung

"New calpains and use thereof (Neue Calpaine und
deren Verwendung)"

am 18. Juni 1999 beim Deutschen Patent- und Markenamt eingereicht.

Die angehefteten Stücke sind eine richtige und genaue Wiedergabe der ursprüng-
lichen Unterlagen dieser Patentanmeldung.

Die Anmeldung hat im Deutschen Patent- und Markenamt vorläufig die Symbole
C 07 K, C 07 H und C 12 Q der Internationalen Patentklassifikation erhalten.

München, den 30. Mai 2000

Deutsches Patent- und Markenamt

Der Präsident

Im Auftrag

Aktenzeichen: 199 28 021.5

Claims

1. Polypeptide having the amino acid sequence SEQID NO:2
- 5 2. Polynucleotide sequence coding for a polypeptide according to Claim 1
3. Polynucleotide sequence having the sequence SEQID NO:1
- 10 4. Use of a polypeptide according to Claim 1 for identifying agents which can inhibit the enzymatic activity of this polypeptide.
- 15 5. A method for identifying compounds which inhibit the enzymatic activity of a polypeptide according to Claim 1 comprising
 - 20 (a) comparing the amount of enzymatic activity of CAPN11 in the presence of the compound with the amount of enzymatic activity of CAPN11 in the absence of the compound and
 - 25 (b) selecting compounds which change the amount of enzymatic activity of CAPN11 compared to the enzymatic activity of CAPN11 in the absence of the compound.
6. Use of compounds identified by the method according to Claim 5 for treatment of male fertility disorders.

30

35

40

New calpains and use thereof

The invention relates to a new mammalian calpain, CAPN11, its
5 synthesis and the use thereof.

Calpains are a superfamily of related proteins some of which have been shown to function as calcium-dependent cysteine proteases. In mammals, eight different calpains have been identified.

10

Calpains constitute a family of intracellular calcium-dependent cysteine proteases. An increasing number of mammalian calpain homologs have been identified and individual members can be classified into four classes based on physical structure and

15 predicted properties. The class A 'classical calpains', CAPN1, CAPN2, CAPN3 (p94), CAPN8 (nCL-2) and CAPN9 (nCL-4) are probably

all protease-active and Ca^{2+} -dependent. They consist of a variable large (80kDa) and an invariant small (30kDa) subunit.

The class B and D calpains CAPN5 (6,15) and CAPN7 (8) are

20 protease-active but most likely Ca^{2+} -independent, the class C calpain CAPN6 probably possesses no protease activity. Calpains

can also be categorized on the basis of their expression patterns with CAPN3, CAPN6, CAPN8 and CAPN9 exhibiting some tissue-specificity. The function of the calpains is unknown although

25 they have been associated with a wide variety of physiological processes and pathological conditions (reviewed in Ref. 17).

Identification of the entire spectrum of calpain family members is essential to elucidate their function and evolutionary

history.

30

The invention relates to the new polypeptide CAPN11 having the amino acid sequence disclosed in SEQIDNO:2.

The new calpain CAPN11 protein possesses the features typical

35 of calpains including potential protease and calcium-binding domains. It exhibits a highly restricted tissue distribution

with the major site of expression being testis. Radiation hybrid mapping localized the gene to human chromosome 6, within a region mapped to p12. Phylogenetic analysis suggests that, in mammals,

40 CAPN11 is most closely related to CAPN1 and CAPN2.

However, of the calpain sequences available, the predicted CAPN11 sequence exhibits greatest homology to the chicken μ/m calpain.

Thus CAPN11 may be the human ortholog of μ/m calpain. The disco-

45 very of this new calpain emphasizes the complexity of the calpain family with members being distinguished on the basis of protease

activity, calcium dependence and tissue expression.

2

The cDNA nucleotide sequence of the CAPN11 gene contains 2338 nucleotides (SEQ ID NO:1). The cDNA sequence was confirmed to be derived from a single mRNA by the successful amplification of the entire predicted coding region from human testis cDNA using flanking primers. Multiple cDNA clones were sequenced in their entirety to exclude any PCR-based artifacts.

One large open reading frame exists which encodes a protein of 702 amino acids (Mr of 80 kDa) (Fig. 1). The amino acid sequence shows similarity to the large subunit of members of the calpain family (Fig. 1). The protein can be subdivided into the four domains typical of calpain. Domain II shows the characteristics of a protease domain and the predicted amino acid sequence possesses the three amino acid residues (Cys102, His259 and Asn283) which are part of the active site of cysteine proteases (2). All five Ca^{2+} -binding sequences reported for CAPN2 (4,12) are conserved to some extent in the amino acid sequence (Fig. 1). Thus, this protein is likely to have protease and calcium-binding ability. A comparison of the predicted amino acid sequence with that of all other calpains revealed greatest sequence homology (57.5%) to chicken μ/m calpain. Of the mammalian calpains, the most similar was human CAPN1 (54.3% homology). The least similar human calpain, with only 18.7% homology, was CAPN6. The gene corresponding to this cDNA has been designated CAPN11 by the Human Gene Nomenclature Committee.

The complete amino acid sequences of all the identified human calpains were subjected to phylogenetic analysis. The results enable the human calpains to be classified into four major evolutionary groups (Fig. 2). The first group is represented by CAPN5, CAPN6, CAPN7 and CAPN8, the second by CAPN1 and CAPN2, the third group by CAPN3 and CAPN9 and the fourth contains CAPN11. Thus, the phylogenetic analysis suggests that CAPN11 represents a distinct calpain subfamily.

Expression of CAPN11 in human tissues was evaluated by Northern and RNA dot blot analysis. Of the 50 tissue RNAs tested, the CAPN11 mRNA was expressed at highest levels in testis (Fig. 3A). The specificity of this signal was verified by northern blot analysis and corresponded to an approximately 3Kb mRNA (Fig. 3D). Much weaker signals were detected in thymus and mammary gland but the significance of these is unclear as further investigation of thymus RNA using northern blot analysis did not reveal any signal despite long exposure times (Fig. 3D and data not shown). One possible explanation is that this weak signal is the result of cross-hybridization to related mRNAs. Nevertheless, testis is the major expression site of CAPN11 although we cannot rule out the

3

possibility that the gene is expressed in other tissues which were not tested.

We determined the chromosome location of the human CAPN11 gene. Using PCR with primers specific for the human CAPN11 nucleotide sequence the gene was mapped to chromosome six with a human/rodent somatic cell hybrid mapping panel (Correll Cell Repositories). With radiation hybrid mapping using the Stanford G3 medium resolution panel (Research Genetics Inc.) and the data-
base at the Stanford Human Genome Center (shgc-www.stanford.edu) the gene was localized five centirays from the marker SHGC-32834 on this chromosome (LOD Score 12.87). This marker is located in the interval between the microsatellite markers D6S1616 (59.6 cM) and D6S427 (73.9 cM) (7) and a marker in this interval, D6S269, has been mapped cytogenetically to 6p12 (5). Thus CAPN11 is located on chromosome 6 in the vicinity of p12. No other calpain gene has been located on this chromosome.

The chicken μ /m calpain was the first member of the calpain family to be cloned (16). It was originally designated as m-calpain but reclassified after the identification of other chicken calpains most likely orthologous to the mammalian μ - and m-calpains (18). A mammalian μ /m calpain has remained elusive but as CAPN11 shows greater homology to chicken μ /m calpain than to any of the mammalian calpains it may be its ortholog.

There are now five calpains which exhibit some degree of tissue-specificity - CAPN3 (skeletal muscle), CAPN6 (placenta), CAPN8 (possibly smooth muscle), CAPN9 (stomach and small intestine) and CAPN11 (testis). Numerous proteases have been identified in testis and have been proposed to participate in processes such as tissue reorganization (20), regulation of spermatogenesis (14), penetration of the zona pellucida by sperm (10) and fertility (13). Many of these activities are, however, dependent on secreted proteases and CAPN11 is likely to be localized intracellularly. In testis it could participate in processes with which calpains have been associated in other tissues such as germ cell apoptosis (3) or regulation of testis-specific transcription factors.

Another aspect of this invention is the use of the polypeptide CAPN11 for identifying agents which can inhibit the enzymatic activity of this polypeptide, so called calpain-inhibitors, especially those calpain inhibitors which are selective for CAPN11. Selectivity means that those calpain inhibitors inhibit

the activity of CAPN11 stronger than the activity of other calpains mentioned above, preferably at least 10 times, more preferred 25 times stronger.

The enzymatic activity of CAPN11 is a Ca-dependent protease activity.

Another aspect of the invention is a method for identifying compounds which inhibit enzymatic activity of a polypeptide according to claim 1 comprising

10

(a) comparing the amount of enzymatic activity of CAPN11 in the presence of the compound with the amount of enzymatic activity of CAPN11 in the absence of the compound and

15 (b) selecting compounds which change the amount of enzymatic activity of CAPN11 compared to the enzymatic activity of CAPN11 in the absence of the compound.

The inhibiting compounds identified by the method mentioned above are useful for the treatment of diseases which are associated or linked with an unphysiologically elevated activity of CAPN11 such as male infertility.

The dosage and the treatment regimen of those inhibitors have to be determined by routine procedures which are well known from other protease inhibitors.

REFERENCES

- 30 1. Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990). Basic local alignment sequencing tool. J. Mol. Biol. 215:403-410.
2. Berti, P. J. and Storer, A. C. (1995). Alignment/Phylogeny of the papain superfamily of cysteine proteases. J. Mol. Biol. 246: 273-283.
- 35 3. Billig H., Chun S.Y., Eisenhauer K. and Hsueh A.J. (1996). Gonadal cell apoptosis: hormone-regulated cell demise. Hum. Reprod. Update 2:103-117.
4. Blanchard, H., Grochulski, P., Li, Y., Arthur, J.S.C., Davies, P.L., Elce, J.S. & Cygler, M. (1997). Structure of a 40 Ca²⁺-binding domain reveals a novel EF-hand and Ca²⁺-induced conformational changes. Nature Structural Biology 4: 532-538.
5. Bray-Ward, P., Menninger, J., Lieman, T., Desai, T., Mokady, N., Banks, A. & Ward, D.C. (1996). Integration of the cyto- 45 genetic, genetic and physical maps of the human genome by FISH mapping of CEPH YAC clones. Genomics 32: 1-14.

6. Dear, N., Matena, K., Vingron, M. and Boehm, T. (1997). A new subfamily of vertebrate calpains lacking a calmodulin-like domain: Implications for calpain regulation and evolution. *Genomics* 45:175-184.
- 5 7. Deloukas, P. et al. (1998). A physical map of 30,000 human genes. *Science* 282: 744-746.
8. Franz, T., Vingron, M., Boehm, T. and Dear, T.N. (1999). Capn7: A highly divergent vertebrate calpain with a novel C-terminal domain. *Mamm. Genome*, in press.
- 10 9. Frohman, M. A., Dush, M. K. and Martin, G. R. (1988). Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. *Proc. Natl. Acad. Sci. USA* 85: 8998-9002.
10. Kohno, N., Yamagata, K., Yamada, S., Kasiwabara, S., Sakai, Y. and Baba, T. (1998). Two novel testicular serine proteases, TESP1 and TESP2, are present in the mouse sperm acrosome. *Biochem. Biophys. Res. Commun.* 245:658-665.
- 15 11. Kozak, M. (1996). Interpreting cDNA sequences: some insights from studies on translation. *Mamm. Genome* 7: 563-574.
- 20 12. Lin, G.-D., Chattopadhyay, D., Maki, M., Wang, K.K.W., Carson, M., Jin, L., Yuen, P.-W., Takano, E., Hatanaka, M., DeLucas, L.J. & Narayana, S.V.L. (1997). Crystal structure of calcium bound domain VI of calpain at 1.9 Å resolution and its role in enzyme assembly, regulation, and inhibitor binding. *Nature Structural Biology* 4: 539-547.
- 25 13. Mbikay, M., Tadros, H., Ishida, N., Lerner, C.P., De Lamirande, E., Chen, A., El-Alfy, M., Clermont, Y., Seidah, N.G., Chrétien, M., Gagnon, C. and Simpson, E.M. (1997). Impaired fertility in mice deficient for the testicular germ-cell protease PC4. *Proc. Natl. Acad. Sci. USA* 94:6842-6846.
- 30 14. Monsees, T.K., Gornig, M., Schill, W.B. and Miska, W. (1998). Possible involvement of proteases in the regulation of spermatogenesis. *Andrologia* 30:185-191.
- 35 15. Mugita, N., Kimura, Y., Ogawa, M., Saya, H. and Nakao, M. (1997). Identification of a novel, tissue-specific calpain htra-3; a human homologue of the *Caenorhabditis elegans* sex determination gene. *Biochem. Biophys. Res. Comm.* 239:845-850.
- 40 16. Ohno, S., Emori, Y., Imajoh, S., Kawasaki, H., Kisaragi, M. and Suzuki, K. (1984). Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein? *Nature* 312: 566-570.
- 45 17. Ono, Y., Sorimachi, H. and Suzuki, K. (1998). Structure and physiology of calpain, an enigmatic protease. *Biochem. Biophys. Res. Commun.* 245:289-294.

6

18. Sorimachi, H., Tsukahara, T., Okada-Ban, M., Sugita, H., Ishiura, S. and Suzuki, K. (1995). Identification of a third ubiquitous calpain species - chicken muscle expresses four distinct calpains. *Biochim. Biophys. Acta* 1261: 381-393.
- 5 19. Thompson J.D., Higgins D.G. and Gibson T.J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucl. Acids Res.* 22:4673-4680
- 10 20. Tohonen, V., Osterlund, C. and Nordqvist, K. (1998). Testatin: A cystatin-related gene expressed during early testis development. *Proc Natl. Acad. Sci. USA* 95:14208-14213.

15 Figures

FIG. 1. Alignment of the predicted amino acid sequence of CAPN11 to other human calpains. Multiple alignment of amino acid sequences was carried out using CLUSTAL W (19). The proposed initiation methionine for CAPN11 (GGAatgG) conforms to the minimal consensus sequence for the translational start site (RNNatgG, where R is a purine; Ref. 11). Amino acids identical in the other proteins with those of CAPN11 shaded. Dashes indicate gaps introduced to maximize alignment. Arrow heads indicate the three conserved amino acids which are part of the active site of calpains. The potential EF-hand calcium-binding domains of CAPN8 are underlined and numbered sequentially. The arbitrary domains of calpain are indicated. Not shown are the sequences for CAPN4 and CAPN7 which have only been identified in rat and mouse respectively. The published CAPN6 sequence was not included as it is only partial. The alternative names and accession numbers for the calpains aligned are given in the legend to Fig. 2.

FIG. 2. Unrooted phylogenetic tree of the human calpain large subunit family. Analysis was performed using the PAUP program and the tree assembled with CLUSTREE from the HUSAR server at the German Cancer Research Center, Heidelberg (www.dkfz-heidelberg.de). Lengths of horizontal lines are proportional to the inferred phylogenetic distances; vertical lines have no significance. 1000 bootstrap repetitions were performed and values are shown at the inner nodes. The Capn7 sequence is that of the mouse as little human nucleotide and protein sequence is available. Nevertheless the human ortholog does exist (see Ref. 8) justifying the use of the mouse sequence for this comparison. The partial human CAPN8 sequence is the predicted translation from the EST clone AA026030 (Hillier et al., 1995, The WashU-Merck EST Project, unpublished results). An amino acid translation of

7

this clone exhibits high similarity to the rat Capn8 sequence. No bootstrapping was performed with this sequence as it is much shorter than the others and thus the bootstrap value can not be meaningfully compared to the values derived from full-length sequence comparisons. The nomenclature specified by the Human Gene Nomenclature Committee is used. Previous names for the various calpains are: CAPN1 - m-calpain; CAPN2 - m-calpain; CAPN3 - p94, nCL-1; CAPN8, nCL-2; CAPN9, nCL-4. The EMBL accession numbers for the calpain sequences used are CAPN1 (P17655), CAPN2 (P07384), CAPN3 (P20807), CAPN5 (Y10656), CAPN6 (Y12582), Capn7 (AJ012475) and CAPN9 (AF022799).

FIG. 3. Expression of CAPN11. A 32P-labeled DNA probe containing an 800 base-pair segment of the human CAPN11 cDNA coding sequence was hybridized to a Master Blot (A), a nylon filter containing dot blots of RNAs from 50 different human tissues, or a Clontech Multiple Tissue Northern Blot (D). Filters were washed at high stringency (6xSSC, 65°C). The precise location of the various RNAs on the dot blot filter is shown schematically (C). RNAs on the northern blot are indicated above the relevant lanes. The dot blot and northern blot were rehybridized with human ubiquitin (B) and b-actin DNA probes respectively to confirm amounts of poly(A+) RNA loaded. For the northern blot, the position of the size markers (in kilobases) are indicated. The exposure times were: A, 72 hours; B, 24 hours; D, 48 hours. PBL = peripheral blood leukocytes.

30

35

40

45

8

SEQUENCE LISTING

<110> BASF Aktiengesellschaft

<120> Testis specific calpain

<130> OZ0050/

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 2338

<212> DNA

<213> Homo sapiens

<220>

<221> 5'UTR

<222> (1)..(103)

<220>

<221> CDS

<222> (104)..(2212)

<220>

<221> 3'UTR

<222> (2213)..(2338)

<400> 1

ctccccaggg ccgagtccttc cggagtcagc agagagcctg gatggatcac aggaggataa 60

gcctcggggc tcattgtgcgg agcccacttt tactgatacg gga atg gtg gct cac 115
Met Val Ala His
1

ata aac aac agc cgg ctc aag gcc aag ggc gtg ggc cag cac gac aac 163
Ile Asn Asn Ser Arg Leu Lys Ala Lys Gly Val Gly Gln His Asp Asn
5 10 15 20

gcc cag aac ttt ggt aac cag agc ttt gag gag ctg cga gca gcc tgt 211
Ala Gln Asn Phe Gly Asn Gln Ser Phe Glu Glu Leu Arg Ala Ala Cys
25 30 35

cta aga aag ggg gag ctc ttc gag gac ccc tta ttc cct gct gaa ccc 259
Leu Arg Lys Gly Glu Leu Phe Glu Asp Pro Leu Phe Pro Ala Glu Pro
40 45 50

agc tca ctg ggc ttc aag gac ctg ggc ccc aac tcc aaa aat gtg cag 307
Ser Ser Leu Gly Phe Lys Asp Leu Gly Pro Asn Ser Lys Asn Val Gln
55 60 65

aac atc tcc tgg cag cgg ccc aag gat atc ata aac aac cct cta ttc 355
Asn Ile Ser Trp Gln Arg Pro Lys Asp Ile Ile Asn Asn Pro Leu Phe
70 75 80

atc atg gat ggg att tct cca aca gac atc tgc cag ggg atc ctc ggg 403

9

Ile	Met	Asp	Gly	Ile	Ser	Pro	Thr	Asp	Ile	Cys	Gln	Gly	Ile	Leu	Gly		
85					90					95					100		
gac	tgc	tgg	ctg	ctg	gct	gcc	atc	ggc	tcc	ctt	acc	acc	tgc	ccc	aaa	451	
Asp	Cys	Trp	Leu	Leu	Ala	Ala	Ile	Gly	Ser	Leu	Thr	Thr	Cys	Pro	Lys		
				105					110					115			
ctg	cta	tac	cgc	gtg	gtg	ccc	aga	gga	cag	agc	ttc	aag	aaa	aac	tat	499	
Leu	Leu	Tyr	Arg	Val	Val	Pro	Arg	Gly	Gln	Ser	Phe	Lys	Lys	Asn	Tyr		
			120					125					130				
gct	ggc	atc	ttc	cat	ttt	cag	att	tgg	cag	ttt	gga	cag	tgg	gtg	aac	547	
Ala	Gly	Ile	Phe	His	Phe	Gln	Ile	Trp	Gln	Phe	Gly	Gln	Trp	Val	Asn		
		135					140					145					
gtg	gtg	gta	gat	gac	cgg	ctg	ccc	aca	aag	aat	gac	aag	ctg	gtg	ttt	595	
Val	Val	Val	Asp	Asp	Arg	Leu	Pro	Thr	Lys	Asn	Asp	Lys	Leu	Val	Phe		
		150				155					160						
gtg	cac	tca	acc	gaa	cgc	agt	gag	ttc	tgg	agt	gcc	ctg	ctg	gag	aag	643	
Val	His	Ser	Thr	Glu	Arg	Ser	Glu	Phe	Trp	Ser	Ala	Leu	Leu	Glu	Lys		
165					170					175					180		
gcg	tat	gcc	aag	ctg	agt	ggg	tcc	tat	gaa	gca	ttg	tca	ggg	ggc	agt	691	
Ala	Tyr	Ala	Lys	Leu	Ser	Gly	Ser	Tyr	Glu	Ala	Leu	Ser	Gly	Gly	Ser		
				185					190					195			
acc	atg	gag	ggc	ctt	gag	gac	ttc	aca	gga	ggc	gtg	gcc	cag	agc	ttc	739	
Thr	Met	Glu	Gly	Leu	Glu	Asp	Phe	Thr	Gly	Gly	Val	Ala	Gln	Ser	Phe		
			200					205					210				
caa	ctc	cag	agg	ccc	cct	cag	aac	ctg	ctc	agg	ctc	ctt	agg	aag	gcc	787	
Gln	Leu	Gln	Arg	Pro	Pro	Gln	Asn	Leu	Leu	Arg	Leu	Leu	Arg	Lys	Ala		
			215				220					225					
gtg	gag	cga	tcc	tcc	ctc	atg	ggg	tgc	tcc	att	gaa	gtc	acc	agt	gat	835	
Val	Glu	Arg	Ser	Ser	Leu	Met	Gly	Cys	Ser	Ile	Glu	Val	Thr	Ser	Asp		
			230			235					240						
agt	gaa	ctg	gaa	tcc	atg	act	gac	aag	atg	ctg	gtg	aga	ggg	cac	gct	883	
Ser	Glu	Leu	Glu	Ser	Met	Thr	Asp	Lys	Met	Leu	Val	Arg	Gly	His	Ala		
145					250					255					260		
tac	tct	gtg	act	ggc	ctt	cag	gat	gtc	cac	tac	aga	ggc	aaa	atg	gaa	931	
Tyr	Ser	Val	Thr	Gly	Leu	Gln	Asp	Val	His	Tyr	Arg	Gly	Lys	Met	Glu		
				265					270					275			
aca	ctg	att	cgg	gtc	cgg	aat	ccc	tgg	ggc	cgg	att	gag	tgg	aat	gga	979	
Thr	Leu	Ile	Arg	Val	Arg	Asn	Pro	Trp	Gly	Arg	Ile	Glu	Trp	Asn	Gly		
			280					285					290				
gct	tgg	agt	gac	agt	gcc	agg	gag	tgg	gaa	gag	gtg	gcc	tca	gac	atc	1027	
Ala	Trp	Ser	Asp	Ser	Ala	Arg	Glu	Trp	Glu	Glu	Val	Ala	Ser	Asp	Ile		
			295				300					305					
cag	atg	cag	ctg	ctg	cac	aag	acg	gag	gac	ggg	gag	ttc	tgg	atg	tcc	1075	
Gln	Met	Gln	Leu	Leu	His	Lys	Thr	Glu	Asp	Gly	Glu	Phe	Trp	Met	Ser		
			310			315					320						
tac	caa	gat	ttc	ctg	aac	aac	ttc	acg	ctc	ctg	gag	atc	tgc	aac	ctc	1123	

10

Tyr	Gln	Asp	Phe	Leu	Asn	Asn	Phe	Thr	Leu	Leu	Glu	Ile	Cys	Asn	Leu		
325					330					335					340		
acg	cct	gat	aca	ctc	tct	ggg	gac	tac	aag	agc	tac	tgg	cac	acc	acc	1171	
Thr	Pro	Asp	Thr	Leu	Ser	Gly	Asp	Tyr	Lys	Ser	Tyr	Trp	His	Thr	Thr		
				345					350					355			
ttc	tac	gag	ggc	agc	tgg	cgc	aga	ggc	agc	tcc	gca	ggg	ggc	tgc	agg	1219	
Phe	Tyr	Glu	Gly	Ser	Trp	Arg	Arg	Gly	Ser	Ser	Ala	Gly	Gly	Cys	Arg		
				360				365						370			
aac	cac	cct	ggc	acg	ttc	tgg	acc	aac	ccc	cag	ttt	aag	atc	tct	ctt	1267	
Asn	His	Pro	Gly	Thr	Phe	Trp	Thr	Asn	Pro	Gln	Phe	Lys	Ile	Ser	Leu		
				375				380						385			
cct	gag	ggg	gat	gac	cca	gag	gat	gac	gca	gag	ggc	aat	gtt	gtg	gtc	1315	
Pro	Glu	Gly	Asp	Asp	Pro	Glu	Asp	Asp	Ala	Glu	Gly	Asn	Val	Val	Val		
				390				395				400					
tgc	acc	tgc	ctg	gtg	gcc	cta	atg	cag	aag	aac	tgg	cgg	cat	gca	cgg	1363	
Cys	Thr	Cys	Leu	Val	Ala	Leu	Met	Gln	Lys	Asn	Trp	Arg	His	Ala	Arg		
405					410					415					420		
cag	cag	gga	gcc	cag	ctg	cag	acc	att	ggc	ttt	gtc	ctc	tac	gcg	gtc	1411	
Gln	Gln	Gly	Ala	Gln	Leu	Gln	Thr	Ile	Gly	Phe	Val	Leu	Tyr	Ala	Val		
				425					430					435			
cca	aaa	gag	ttt	cag	aac	att	cag	gat	gtc	cac	ttg	aag	aag	gaa	ttc	1459	
Pro	Lys	Glu	Phe	Gln	Asn	Ile	Gln	Asp	Val	His	Leu	Lys	Lys	Glu	Phe		
				440				445						450			
ttc	acg	aag	tat	cag	gac	cac	ggc	ttc	tca	gag	atc	ttc	acc	aac	tca	1507	
Phe	Thr	Lys	Tyr	Gln	Asp	His	Gly	Phe	Ser	Glu	Ile	Phe	Thr	Asn	Ser		
				455				460						465			
cgg	gag	gtg	agc	agc	caa	ctc	cgg	ctg	cct	ccg	ggg	gaa	tat	atc	att	1555	
Arg	Glu	Val	Ser	Ser	Gln	Leu	Arg	Leu	Pro	Pro	Gly	Glu	Tyr	Ile	Ile		
						475					480						
att	ccc	tcc	acc	ttt	gag	cca	cac	aga	gat	gct	gac	ttc	ctg	ctt	cgg	1603	
Ile	Pro	Ser	Thr	Phe	Glu	Pro	His	Arg	Asp	Ala	Asp	Phe	Leu	Leu	Arg		
485					490					495					500		
gtc	ttc	acc	gag	aag	cac	agc	gag	tca	tgg	gaa	ttg	gat	gaa	gtc	aac	1651	
Val	Phe	Thr	Glu	Lys	His	Ser	Glu	Ser	Trp	Glu	Leu	Asp	Glu	Val	Asn		
				505					510					515			
tat	gct	gag	caa	ctc	caa	gag	gaa	aag	gtc	tct	gag	gat	gac	atg	gac	1699	
Tyr	Ala	Glu	Gln	Leu	Gln	Glu	Glu	Lys	Val	Ser	Glu	Asp	Asp	Met	Asp		
				520				525						530			
cag	gac	ttc	cta	cat	ttg	ttt	aag	ata	gtg	gca	gga	gag	ggc	aag	gag	1747	
Gln	Asp	Phe	Leu	His	Leu	Phe	Lys	Ile	Val	Ala	Gly	Glu	Gly	Lys	Glu		
				535				540						545			
ata	ggg	gtg	tat	gag	ctc	cag	agg	ctg	ctc	aac	agg	atg	gcc	atc	aaa	1795	
Ile	Gly	Val	Tyr	Glu	Leu	Gln	Arg	Leu	Leu	Asn	Arg	Met	Ala	Ile	Lys		
				550				555						560			
ttc	aaa	agc	ttc	aag	acc	aag	ggc	ttt	ggc	ctg	gat	gct	tgc	cgc	tgc	1843	

11

Phe Lys Ser Phe Lys Thr Lys Gly Phe Gly Leu Asp Ala Cys Arg Cys
 565 570 575 580

atg atc aac ctc atg gat aaa gat ggc tct ggc aag ctg ggg ctt cta 1891
 Met Ile Asn Leu Met Asp Lys Asp Gly Ser Gly Lys Leu Gly Leu Leu
 585 590 595

gag ttc aag atc ctg tgg aaa aaa ctc aag aaa tgg atg gac atc ttc 1939
 Glu Phe Lys Ile Leu Trp Lys Lys Leu Lys Lys Trp Met Asp Ile Phe
 600 605 610

aga gag tgt gac cag gac cat tca ggc acc ttg aac tcc tat gag atg 1987
 Arg Glu Cys Asp Gln Asp His Ser Gly Thr Leu Asn Ser Tyr Glu Met
 615 620 625

cgc ctg gtt att gag aaa gca ggc atc aag ctg aac aac aag gta atg 2035
 Arg Leu Val Ile Glu Lys Ala Gly Ile Lys Leu Asn Asn Lys Val Met
 630 635 640

cag gtc ctg gtg gcc agg tat gca gat gat gac ctg atc ata gac ttt 2083
 Gln Val Leu Val Ala Arg Tyr Ala Asp Asp Asp Leu Ile Ile Asp Phe
 645 650 655 660

gac agc ttc atc agc tgt ttc ctg agg cta aag acc atg ttc aca ttc 2131
 Asp Ser Phe Ile Ser Cys Phe Leu Arg Leu Lys Thr Met Phe Thr Phe
 665 670 675

ttt cta acc atg gac ccc aag aat act ggc cat att tgc ttg agc ctg 2179
 Phe Leu Thr Met Asp Pro Lys Asn Thr Gly His Ile Cys Leu Ser Leu
 680 685 690

gaa cag tgg ctg cag atg acc atg tgg gga tag aggcgctgta ggagcctgggt 2232
 Glu Gln Trp Leu Gln Met Thr Met Trp Gly
 695 700

catctctacc agcagcagca gcagcgaggt tctagcccag gaggggtgggg tgcttcttgt 2292

agccctcagc tctccagtct ctgctgatga aatgggatcc aggtgg 2338

<210> 2
 <211> 702
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Val Ala His Ile Asn Asn Ser Arg Leu Lys Ala Lys Gly Val Gly
 1 5 10 15

Gln His Asp Asn Ala Gln Asn Phe Gly Asn Gln Ser Phe Glu Glu Leu
 20 25 30

Arg Ala Ala Cys Leu Arg Lys Gly Glu Leu Phe Glu Asp Pro Leu Phe
 35 40 45

Pro Ala Glu Pro Ser Ser Leu Gly Phe Lys Asp Leu Gly Pro Asn Ser
 50 55 60

Lys Asn Val Gln Asn Ile Ser Trp Gln Arg Pro Lys Asp Ile Ile Asn
 65 70 75 80

12

Asn Pro Leu Phe Ile Met Asp Gly Ile Ser Pro Thr Asp Ile Cys Gln
85 90 95

Gly Ile Leu Gly Asp Cys Trp Leu Leu Ala Ala Ile Gly Ser Leu Thr
100 105 110

Thr Cys Pro Lys Leu Leu Tyr Arg Val Val Pro Arg Gly Gln Ser Phe
115 120 125

Lys Lys Asn Tyr Ala Gly Ile Phe His Phe Gln Ile Trp Gln Phe Gly
130 135 140

Gln Trp Val Asn Val Val Val Asp Asp Arg Leu Pro Thr Lys Asn Asp
145 150 155 160

Lys Leu Val Phe Val His Ser Thr Glu Arg Ser Glu Phe Trp Ser Ala
165 170 175

Leu Leu Glu Lys Ala Tyr Ala Lys Leu Ser Gly Ser Tyr Glu Ala Leu
180 185 190

Ser Gly Gly Ser Thr Met Glu Gly Leu Glu Asp Phe Thr Gly Gly Val
195 200 205

Ala Gln Ser Phe Gln Leu Gln Arg Pro Pro Gln Asn Leu Leu Arg Leu
210 215 220

Leu Arg Lys Ala Val Glu Arg Ser Ser Leu Met Gly Cys Ser Ile Glu
225 230 235 240

Val Thr Ser Asp Ser Glu Leu Glu Ser Met Thr Asp Lys Met Leu Val
245 250 255

Arg Gly His Ala Tyr Ser Val Thr Gly Leu Gln Asp Val His Tyr Arg
260 265 270

Gly Lys Met Glu Thr Leu Ile Arg Val Arg Asn Pro Trp Gly Arg Ile
275 280 285

Glu Trp Asn Gly Ala Trp Ser Asp Ser Ala Arg Glu Trp Glu Glu Val
290 295 300

Ala Ser Asp Ile Gln Met Gln Leu Leu His Lys Thr Glu Asp Gly Glu
305 310 315 320

Phe Trp Met Ser Tyr Gln Asp Phe Leu Asn Asn Phe Thr Leu Leu Glu
325 330 335

Ile Cys Asn Leu Thr Pro Asp Thr Leu Ser Gly Asp Tyr Lys Ser Tyr
340 345 350

Trp His Thr Thr Phe Tyr Glu Gly Ser Trp Arg Arg Gly Ser Ser Ala
355 360 365

Gly Gly Cys Arg Asn His Pro Gly Thr Phe Trp Thr Asn Pro Gln Phe
370 375 380

Lys Ile Ser Leu Pro Glu Gly Asp Asp Pro Glu Asp Asp Ala Glu Gly
385 390 395 400

13

Asn Val Val Val Cys Thr Cys Leu Val Ala Leu Met Gln Lys Asn Trp
405 410 415

Arg His Ala Arg Gln Gln Gly Ala Gln Leu Gln Thr Ile Gly Phe Val
420 425 430

Leu Tyr Ala Val Pro Lys Glu Phe Gln Asn Ile Gln Asp Val His Leu
435 440 445

Lys Lys Glu Phe Phe Thr Lys Tyr Gln Asp His Gly Phe Ser Glu Ile
450 455 460

Phe Thr Asn Ser Arg Glu Val Ser Ser Gln Leu Arg Leu Pro Pro Gly
465 470 475 480

Glu Tyr Ile Ile Ile Pro Ser Thr Phe Glu Pro His Arg Asp Ala Asp
485 490 495

Phe Leu Leu Arg Val Phe Thr Glu Lys His Ser Glu Ser Trp Glu Leu
500 505 510

Asp Glu Val Asn Tyr Ala Glu Gln Leu Gln Glu Glu Lys Val Ser Glu
515 520 525

Asp Asp Met Asp Gln Asp Phe Leu His Leu Phe Lys Ile Val Ala Gly
530 535 540

Glu Gly Lys Glu Ile Gly Val Tyr Glu Leu Gln Arg Leu Leu Asn Arg
545 550 555 560

Met Ala Ile Lys Phe Lys Ser Phe Lys Thr Lys Gly Phe Gly Leu Asp
565 570 575

Ala Cys Arg Cys Met Ile Asn Leu Met Asp Lys Asp Gly Ser Gly Lys
580 585 590

Leu Gly Leu Leu Glu Phe Lys Ile Leu Trp Lys Lys Leu Lys Lys Trp
595 600 605

Met Asp Ile Phe Arg Glu Cys Asp Gln Asp His Ser Gly Thr Leu Asn
610 615 620

Ser Tyr Glu Met Arg Leu Val Ile Glu Lys Ala Gly Ile Lys Leu Asn
625 630 635 640

Asn Lys Val Met Gln Val Leu Val Ala Arg Tyr Ala Asp Asp Asp Leu
645 650 655

Ile Ile Asp Phe Asp Ser Phe Ile Ser Cys Phe Leu Arg Leu Lys Thr
660 665 670

Met Phe Thr Phe Phe Leu Thr Met Asp Pro Lys Asn Thr Gly His Ile
675 680 685

Cys Leu Ser Leu Glu Gln Trp Leu Gln Met Thr Met Trp Gly
690 695 700

Abstract

New calpains and use thereof

5

10

15

20

25

30


35

40


45

[illegible]

Fig. 2



• • • • •



THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)